Shenzhen Neptunus Bioengineering Co

Shenzhen Neptunus Bioengineering Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Shenzhen Neptunus Bioengineering Co (000078.SZ) as of Oct 29, 2026 is 15.86. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -17.37 — a change of -191.29% (higher).

EV/EBITDA

15.86

YoY

-191.29%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Shenzhen Neptunus Bioengineering Co is 2025 15.86 . EV/EBITDA (Enterprise Value to EBITDA) of Shenzhen Neptunus Bioengineering Co was 2024 -17.37 . It decreases by -191.29% higher compared to the previous year.

The Shenzhen Neptunus Bioengineering Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
16.03 CNY
Jan 1, 2019
14.68 CNY
Jan 1, 2020
38.63 CNY
Jan 1, 2021
21.43 CNY
Jan 1, 2022
-27.45 CNY
Jan 1, 2023
-13.07 CNY
Jan 1, 2024
-17.37 CNY
Jan 1, 2025
15.86 CNY
The Shenzhen Neptunus Bioengineering Co EV/EBITDA history
YEAREV/EBITDAYoY
15.86-191.29%
-17.37+32.94%
-13.07-52.39%
-27.45-228.10%
21.43-44.53%
38.63+163.10%
14.68-8.40%
16.03+84.91%
8.67-23.00%
11.26-9.46%
12.43-75.41%
50.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Shenzhen Neptunus Bioengineering Co Stock analysis

What does Shenzhen Neptunus Bioengineering Co do? Shenzhen Neptunus Bioengineering Co., Ltd. generates revenue through its pharmaceutical products and healthcare offerings. The company produces anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products, and other pharmaceuticals. It also sells healthcare products, health food, and medical instruments. The primary market for these products is the domestic market, with East China being the main regional focus. The company serves healthcare providers, hospitals, and consumers within China's pharmaceutical sector. Neptunus targets the Chinese domestic market, emphasizing East China as its core region. Its product portfolio spans multiple therapeutic areas including oncology, cardiology, respiratory care, and infection control. The company's distribution network focuses on reaching hospitals and healthcare facilities across China, particularly in the East China region. The firm's health food and medical instrument lines complement its pharmaceutical business, creating diversified revenue streams within the healthcare industry. The business model relies on selling established pharmaceutical products alongside healthcare and medical solutions. Anti-tumor products and cardiovascular drugs form key segments of its revenue, supported by marine drugs and respiratory medications. East China's dominance in sales reflects the company's strategic market focus. The company's full-time employee count of 9,874 supports its manufacturing and distribution operations across China's domestic market. Shenzhen Neptunus Bioengineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shenzhen Neptunus Bioengineering Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Shenzhen Neptunus Bioengineering Co is 15.86 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Shenzhen Neptunus Bioengineering Co changed from -17.37 to 15.86, representing a -191.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Shenzhen Neptunus Bioengineering Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Shenzhen Neptunus Bioengineering Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Shenzhen Neptunus Bioengineering Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Shenzhen Neptunus Bioengineering Co